The vaccine doesn't prevent cancer from happening in the first place, but an early-phase trial found it could reduce the odds ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

An experimental cancer vaccine has shown promising results in keeping pancreatic and colorectal cancers from coming back. In ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with ...